Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer

British Journal of Urology(2020)10.1111/bju.15227Source: DataRank Database

Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer is a research paper published in British Journal of Urology (2020). On theSindex it has a DataRank of 0. It has been cited 13 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access13 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.88)OA: greenTopics (52)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (27)

Fatima Karzai ORCID,Munjid Al Harthy,Daniel P. Petrylak ORCID,Joseph W. Kim ORCID,Philip M. Arlen

Live enrichment

PubMed:32969563 PMC:PMC8265825 OpenAlex:https://openalex.org/W3088858550

NCATS NIH HHS

Grant: UL1 TR001863

Intramural NIH HHS

Grant: ZIA BC010945

NCI Intramural Program

FWCI

0.88

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8265825

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fbju.15227

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/bju.15227

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1111/bju.15227

Fields of Study

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentCancer Treatment and PharmacologyAgedAged, 80 and overAnilidesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsDocetaxelHumansMaleMiddle AgedNeoplasm MetastasisPrednisoneProstatic Neoplasms, Castration-ResistantPyridinesTreatment Outcome

MeSH Terms

DocetaxelAgedAged, 80 and overAnilidesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleMiddle AgedNeoplasm MetastasisPrednisonePyridinesTreatment OutcomeProstatic Neoplasms, Castration-Resistant

Keywords

DocetaxelCabozantinibMedicineProstate cancerPrednisoneOncologyInternal medicineCastrationAbirateroneCabazitaxelUrologyCancerHormoneAndrogen deprivation therapyAndrogen receptorChemotherapyCombination therapyMetastatic Prostate Cancer#Pcsm#Prostatecancer#Uroonc

Sustainable Development Goals

SDG 0: Good health and well-being